GC Corp. purchased $4.0M of ARTV (indirect holdings)

GC Corp. purchased 347,222 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.52 ($4.00M total) on 2026-05-11.

Original reporting
SEC EDGAR · GC Corp.
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
low confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The only new fact is the size and price of the reported purchase (about $4.0M). There is no accompanying guidance, clinical update, deal, or regulatory action.

02

Market read

Traders may note insider accumulation, but the disclosure lacks fundamental drivers and is unlikely to change valuation expectations on its own.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not explain intent, timing constraints, or whether the buyer’s thesis is tied to near-term catalysts.

Relevance 7/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-11

Background

This is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc., reported by GC Corp as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$ARTVNeutralLow confidence
Context

GC Corp, a 10% owner, filed a Form 4 showing an indirect open-market purchase of 347,222 shares at $11.52.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider transactions can inform positioning, but this disclosure provides no new company-specific operating or financial information.

Market effects

No clear sector read-through from a single insider/affiliate purchase.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine portfolio rebalancing or indirect holdings mechanics rather than a bullish view on Artiva’s prospects.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ARTV).

  • GC Corp

    10% owner reporting an indirect open-market purchase of ARTV shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.